Evaluating the Efficacy and Safety of Octane Aether for Treating Chronic Low Back Pain
A Randomized, Double-blind, Sham-controlled Study to Evaluate the Efficacy and Safety of the Octane [Aether] Bioelectricity Device for the Management of Chronic Low Back Pain
The goal of this clinical trial is to evaluate the safety of the Octane Aether device and to determine whether the device is effective in treating symptoms of non-specific chronic low back pain in adults. The Octane Aether is a wearable device that produces specific magnetic field outputs and is designed for daily use in a home setting. The main objectives of the trial are:
- To measure the change in patient-reported pain scores during active treatment with the device compared to a sham treatment, and
- To define and describe the adverse effects, if any, of the Octane Aether device when administered according to the protocol.
Every participant will evaluate three active output modes and a sham output using the same device. Patient-reported outcomes will inform the effectiveness of each output mode and help identify the need for personalization in magnetic field therapy.
Participants will:
- Use the device at home for 60 minutes every day for 10 weeks,
- Report daily pain scores using an electronic visual analog scale for pain intensity,
- Visit the clinic 5 times over the course of the 13 week trial for checkups and device changes,
- Respond to 3 phone calls for checkups, and
- Fill various questionnaires related to disability, quality of life, and their back pain.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Ontario
-
Kingston, Ontario, Canadá, K7K 0J7
- Kingston Orthopaedic Pain Institute
-
Contato:
- Thomas Gregory
- Número de telefone: 613-507-7246
- E-mail: thomas.gregory@queensu.ca
-
Investigador principal:
- Thomas Gregory
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Able to provide informed consent;
- Aged 18-65;
- Pain intensity of at least 5 on a numerical rating scale (0-10);
- Experiencing chronic low back pain that has persisted for ≥3 months;
- Pain localized primarily to the lumbar spine region;
- Conservative treatments, such as physical therapy, NSAIDs and lifestyle changes, have failed over the past 6 months. Participants are allowed to continue conservative treatments, but changes to use/frequency will be tracked; and
- Must be able to attend 5 in-person clinic appointments over the 13-week study period.
Exclusion Criteria:
- Began using new prescription medication for pain within the past 3 months;
- Lumbar spine surgery (within the past 12 months);
- Body Mass Index (BMI)> 35. The device may have diminished effectiveness and/or may not fit individuals with high BMI;
- Presence of a cardiac pacemaker;
- Pregnancy or breastfeeding;
- Presence of ferromagnetic implants or body piercings (e.g., navel piercings) in the lumbar region, including hip implants/replacements or similar in the pelvic region, that could interfere with device function;
- Inability to put on, adjust, and/or operate the wearable device without assistance;
- Prior use of PEMF, or other electromagnetic field-emitting device, for the treatment of pain symptoms;
- No, or inconsistent, access to internet (emailed surveys are used for daily data collection); and
- Any condition or diagnosis that could in the opinion of the Principal Investigator or delegate interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Sequence Group 1
Participants receive active/sham treatments in the following sequence: EMF A, EMF B, Sham, EMF C
|
The Octane Aether is a body-worn device that generates pulsed magnetic fields of specific characteristics designed to target cellular behaviour in relation to chronic pain signalling. The device features four different output modes (3 active and 1 sham) to enable an investigation of the need for personalized pain management. The specific characteristics of the output modes are blinded from the participants and study team and are labelled here as EMF A, EMF B, EMF C, and Sham. The device firmware is programmed to automatically change the output mode every two weeks. The device produces no sound or thermal effects. When operating in the sham mode, the device appears identical to active output, but no current is applied to the body-worn coil applicator and no magnetic field is generated.
Outros nomes:
|
|
Experimental: Sequence Group 2
Participants receive active/sham treatments in the following sequence: EMF B, EMF C, EMF A, Sham
|
The Octane Aether is a body-worn device that generates pulsed magnetic fields of specific characteristics designed to target cellular behaviour in relation to chronic pain signalling. The device features four different output modes (3 active and 1 sham) to enable an investigation of the need for personalized pain management. The specific characteristics of the output modes are blinded from the participants and study team and are labelled here as EMF A, EMF B, EMF C, and Sham. The device firmware is programmed to automatically change the output mode every two weeks. The device produces no sound or thermal effects. When operating in the sham mode, the device appears identical to active output, but no current is applied to the body-worn coil applicator and no magnetic field is generated.
Outros nomes:
|
|
Experimental: Sequence Group 3
Participants receive active/sham treatments in the following sequence: EMF C, Sham, EMF B, EMF A
|
The Octane Aether is a body-worn device that generates pulsed magnetic fields of specific characteristics designed to target cellular behaviour in relation to chronic pain signalling. The device features four different output modes (3 active and 1 sham) to enable an investigation of the need for personalized pain management. The specific characteristics of the output modes are blinded from the participants and study team and are labelled here as EMF A, EMF B, EMF C, and Sham. The device firmware is programmed to automatically change the output mode every two weeks. The device produces no sound or thermal effects. When operating in the sham mode, the device appears identical to active output, but no current is applied to the body-worn coil applicator and no magnetic field is generated.
Outros nomes:
|
|
Experimental: Sequence Group 4
Participants receive active/sham treatments in the following sequence: Sham, EMF A, EMF C, EMF B
|
The Octane Aether is a body-worn device that generates pulsed magnetic fields of specific characteristics designed to target cellular behaviour in relation to chronic pain signalling. The device features four different output modes (3 active and 1 sham) to enable an investigation of the need for personalized pain management. The specific characteristics of the output modes are blinded from the participants and study team and are labelled here as EMF A, EMF B, EMF C, and Sham. The device firmware is programmed to automatically change the output mode every two weeks. The device produces no sound or thermal effects. When operating in the sham mode, the device appears identical to active output, but no current is applied to the body-worn coil applicator and no magnetic field is generated.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in patient-reported pain scores during active treatment compared to the sham treatment period
Prazo: From start of Treatment Period 1 (Week 2) to end of Treatment Period 4 (Week 9)
|
The difference in the mean pain VAS of scores reported in the second week of each active treatment period and the mean VAS of the second week of the same participant's sham period.
|
From start of Treatment Period 1 (Week 2) to end of Treatment Period 4 (Week 9)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adverse effects associated with the use of the Octane Aether
Prazo: From start of device use (Week 2) to follow-up appointment (Week 13 - end of study)
|
To define and describe the adverse effects of the Octane Aether when administered according to the clinical trial protocol.
Participants and the study team will report adverse events associated with use of the device or device malfunctions.
|
From start of device use (Week 2) to follow-up appointment (Week 13 - end of study)
|
|
Effect of treatment on quality of life and disability index
Prazo: From end of first treatment period (Week 3) to end of fourth treatment period (Week 9)
|
The Octane Aether's effect is evaluated using the Roland-Morris Disability questionnaire, which assesses low back pain's influence on disability and quality of life.
The questionnaire is completed after each active and sham treatment period and compared.
|
From end of first treatment period (Week 3) to end of fourth treatment period (Week 9)
|
|
Net change in perceived pain intensity (start to end)
Prazo: From baseline week (pre-intervention) to end of Treatment Period 4 (Week 9)
|
The change in mean pain VAS scores from the baseline week to the final week of Treatment Period 4 (Week 9).
|
From baseline week (pre-intervention) to end of Treatment Period 4 (Week 9)
|
|
Net effect of intervention on disability index
Prazo: From baseline (Week 1) to end of Treatment Period 4 (Week 9)
|
Change in Roland-Morris Disability questionnaire responses from Baseline to end of Treatment Period 4.
|
From baseline (Week 1) to end of Treatment Period 4 (Week 9)
|
|
Effect of Octane Aether EMF treatment on general health (physical and emotional)
Prazo: From Week 1 to Week 9
|
Participants respond to the RAND 36-item health survey after Week 1 and Week 9 and the change in category scores associated with physical and emotional health and quality of life are analyzed.
|
From Week 1 to Week 9
|
|
Longevity of the effect of Octane Aether treatment
Prazo: From end of device use (Week 11) to follow-up appointment (Week 13)
|
VAS for pain reports are used to assess changes in pain intensity two weeks after the end of intervention use to evaluate whether there is a lasting effect from the treatment.
|
From end of device use (Week 11) to follow-up appointment (Week 13)
|
|
Longevity of the intervention effect on disability and quality of life
Prazo: From end of device use (Week 11) to follow-up appointment (Week 13)
|
Roland-Morris Disability Questionnaire responses are used to evaluate the potential lasting effect of the interventional device after stopping daily use.
|
From end of device use (Week 11) to follow-up appointment (Week 13)
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Effectiveness of EMF A vs B vs C
Prazo: From Treatment Period 1 (Week 2) to 4 (Week 9)
|
Compare the change in pain VAS scores reported from start to finish of each active and sham output mode.
|
From Treatment Period 1 (Week 2) to 4 (Week 9)
|
|
Output mode preference
Prazo: Treatment Period 5 (Week 10)
|
Tally of output mode that each participant chose to repeat during Treatment Period 5. Participants are asked to select their preferred mode.
|
Treatment Period 5 (Week 10)
|
|
Changes in medication use
Prazo: Responses recorded at Baseline and all scheduled appointments (after Week 1, 3, 5, 7, 9, 11, and 13)
|
To assess whether the use of the interventional device affects how participants report using (non-prescription) medication (dosage and frequency).
|
Responses recorded at Baseline and all scheduled appointments (after Week 1, 3, 5, 7, 9, 11, and 13)
|
|
Device performance - Temperature
Prazo: Measurement data exported from the device after the device is returned during the Week 11 appointment.
|
Device performance is assessed by analyzing coil temperature sensor measurements recorded whenever the device is in use.
Temperature data is compared to calibration measurements.
|
Measurement data exported from the device after the device is returned during the Week 11 appointment.
|
|
Device performance - Magnetic Flux Density
Prazo: Measurement data exported from the device after the device is returned during the Week 11 appointment.
|
Device performance is assessed by analyzing magnetic flux density measurements collected using a Hall-effect sensor embedded in the coil applicator.
Magnetic flux density data recorded during each treatment session is compared to calibration measurements as a measure of performance and consistency.
|
Measurement data exported from the device after the device is returned during the Week 11 appointment.
|
|
Device performance - Current
Prazo: Measurement data exported from the device after the device is returned during the Week 11 appointment.
|
Device performance is assessed by analyzing data received from a current sensor that measures the current through the coil applicator.
Current measurements, recorded during each treatment session, are compared to calibration data at the end of the study.
|
Measurement data exported from the device after the device is returned during the Week 11 appointment.
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- Bioelectricity_FP01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .